WuXi PharmaTech Expands Agreement with Merck & Co., Inc.

   Date:2006/12/31

WuXi PharmaTech Co. Ltd., China's leading pharmaceutical R&D service company, announced that Merck & Co., Inc., of Whitehouse Station, NJ, USA, has agreed to extend and expand an agreement through which WuXi provides a variety of chemistry-related R&D services.

The existing agreement between the two companies was signed in 2003. The new expanded agreement, extended till 2010, offers additional opportunities for collaboration, and substantially increases the number of full-time WuXi scientists assisting Merck. A broader range of functional WuXi services including synthesis, process research, and medicinal chemistry, will also be utilized. Merck is one of the largest pharmaceutical companies to seek WuXi's services. Financial terms were not disclosed.

"This is a win-win opportunity for both sides," says Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. ''Our partnership with Merck helps us gain world class experience, and at the same time helps Merck better deploy their R&D resources. This agreement, the result of WuXi's sustained high performance on Merck projects, contributes greatly to our strategic target of becoming a first-class fully integrated R&D service company," continued Dr. Li.

Source:佚名

2005- www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号